KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other Accumulated Expenses (2016 - 2025)

Vertex Pharmaceuticals has reported Other Accumulated Expenses over the past 17 years, most recently at $428.3 million for Q4 2025.

  • Quarterly results put Other Accumulated Expenses at $428.3 million for Q4 2025, up 17.99% from a year ago — trailing twelve months through Dec 2025 was $428.3 million (up 17.99% YoY), and the annual figure for FY2025 was $428.3 million, up 17.99%.
  • Other Accumulated Expenses for Q4 2025 was $428.3 million at Vertex Pharmaceuticals, down from $441.5 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for VRTX hit a ceiling of $648.6 million in Q1 2024 and a floor of $201.4 million in Q3 2021.
  • Median Other Accumulated Expenses over the past 5 years was $336.9 million (2023), compared with a mean of $348.8 million.
  • Biggest five-year swings in Other Accumulated Expenses: surged 72.04% in 2024 and later crashed 40.43% in 2025.
  • Vertex Pharmaceuticals' Other Accumulated Expenses stood at $268.4 million in 2021, then increased by 16.06% to $311.5 million in 2022, then surged by 69.25% to $527.2 million in 2023, then tumbled by 31.15% to $363.0 million in 2024, then grew by 17.99% to $428.3 million in 2025.
  • The last three reported values for Other Accumulated Expenses were $428.3 million (Q4 2025), $441.5 million (Q3 2025), and $425.4 million (Q2 2025) per Business Quant data.